| Abstract: |
Indolent non-Hodgkin lymphomas (NHLs) are among the most prevalent hematologic malignancies; their incidence has been increasing over the last several decades. Because advanced-stage indolent lymphoma is generally incurable, therapy for this group of patients is geared toward chronic management over years. Recently, numerous trials have demonstrated that the combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab can provide superior efficacy to chemotherapy alone. Thus, rituximab-containing regimens are the standard approach for primary therapy in patients with symptomatic advanced disease. As these patients progress and receive multiple rituximab-based regimens over time, new treatment options are needed for this new group of rituximab-pretreated patients. This review focuses on the development of novel therapies for rituximab-pretreated, relapsed or refractory indolent NHL. |
| Keywords: |
cancer survival; survival rate; unclassified drug; overall survival; fludarabine; lenalidomide; prednisone; allogeneic stem cell transplantation; clinical trial; fatigue; neutropenia; review; doxorubicin; placebo; cancer combination chemotherapy; diarrhea; drug efficacy; drug safety; drug withdrawal; monotherapy; treatment duration; antineoplastic agents; disease free survival; combined modality therapy; ibritumomab tiuxetan; rituximab; cancer staging; recurrent cancer; antineoplastic agent; unindexed drug; low drug dose; bortezomib; infection; multiple cycle treatment; neoplasm recurrence, local; protease inhibitors; anemia; bone marrow suppression; blood toxicity; leukopenia; nausea; thrombocytopenia; antineoplastic combined chemotherapy protocols; peripheral neuropathy; combination chemotherapy; bendamustine; cyclophosphamide; vincristine; autologous stem cell transplantation; hematopoietic stem cell transplantation; drug effect; drug resistance, neoplasm; cancer resistance; monoclonal antibody; drug fever; pneumonia; chemotherapy induced emesis; gastrointestinal toxicity; survival time; antibodies, monoclonal; nonhodgkin lymphoma; nonmyeloablative conditioning; iodine 131; lymphoma, non-hodgkin; dosage schedule comparison; drug response; therapy delay; graft versus host reaction; reduced intensity conditioning; single drug dose; cancer relapse; virus infection; drug cytotoxicity; immunologic factors; radioimmunotherapy; tositumomab i 131; alemtuzumab; chlorambucil; granulocytopenia; immunosuppressive agent; upper respiratory tract infection; tositumomab; non-hodgkin lymphoma; cladribine; early intervention; yttrium 90; ofatumumab; ame 133; cd20 antibody; ga 101; humax cd 20; immu 106; immuno 106; monoclonal antibody cd2; monoclonal antibody cd80; pro 70769; treanda; antibodies, monoclonal, murine-derived
|
